Global Peptide Cancer Vaccine Market Size, Manufacturers, Opportunities and Forecast to 2030

Global Peptide Cancer Vaccine Market Size, Manufacturers, Opportunities and Forecast to 2030


Summary

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

According to APO Research, The global Peptide Cancer Vaccine market was estimated at US$ million in 2023 and is projected to reach a revised size of US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

North American market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine.
The Peptide Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Peptide Cancer Vaccine segment by Pipeline
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Peptide Cancer Vaccine segment by Application

Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Peptide Cancer Vaccine Segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts (2019-2030)
1.2.2 Global Peptide Cancer Vaccine Sales Estimates and Forecasts (2019-2030)
1.3 Peptide Cancer Vaccine Market by Pipeline
1.3.1 ITK-1
1.3.2 GRN-1201
1.3.3 TPIV200
1.3.4 TPIV110
1.3.5 UV1
1.3.6 Galinpepimut-S
1.3.7 TARP 27-35
1.3.8 HER-Vaxx
1.3.9 Vx-001
1.3.10 Others
1.4 Global Peptide Cancer Vaccine Market Size by Pipeline
1.4.1 Global Peptide Cancer Vaccine Market Size Overview by Pipeline (2019-2030)
1.4.2 Global Peptide Cancer Vaccine Historic Market Size Review by Pipeline (2019-2024)
1.4.3 Global Peptide Cancer Vaccine Forecasted Market Size by Pipeline (2025-2030)
1.5 Key Regions Market Size by Type
1.5.1 North America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.2 Europe Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
1.5.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)
2 Global Market Dynamics
2.1 Peptide Cancer Vaccine Industry Trends
2.2 Peptide Cancer Vaccine Industry Drivers
2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
2.4 Peptide Cancer Vaccine Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Peptide Cancer Vaccine Revenue (2019-2024)
3.2 Global Top Players by Peptide Cancer Vaccine Sales (2019-2024)
3.3 Global Top Players by Peptide Cancer Vaccine Price (2019-2024)
3.4 Global Peptide Cancer Vaccine Industry Company Ranking, 2022 VS 2023 VS 2024
3.5 Global Peptide Cancer Vaccine Key Company Manufacturing Sites & Headquarters
3.6 Global Peptide Cancer Vaccine Company, Product Type & Application
3.7 Global Peptide Cancer Vaccine Company Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023
3.8.3 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier 3
4 Peptide Cancer Vaccine Regional Status and Outlook
4.1 Global Peptide Cancer Vaccine Market Size and CAGR by Region: 2019 VS 2023 VS 2030
4.2 Global Peptide Cancer Vaccine Historic Market Size by Region
4.2.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2019-2024)
4.2.2 Global Peptide Cancer Vaccine Sales in Value by Region (2019-2024)
4.2.3 Global Peptide Cancer Vaccine Sales (Volume & Value), Price and Gross Margin (2019-2024)
4.3 Global Peptide Cancer Vaccine Forecasted Market Size by Region
4.3.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2025-2030)
4.3.2 Global Peptide Cancer Vaccine Sales in Value by Region (2025-2030)
4.3.3 Global Peptide Cancer Vaccine Sales (Volume & Value), Price and Gross Margin (2025-2030)
5 Peptide Cancer Vaccine by Application
5.1 Peptide Cancer Vaccine Market by Application
5.1.1 Breast Cancer
5.1.2 Lung Cancer
5.1.3 Melanoma
5.1.4 Prostate Cancer
5.1.5 Others
5.2 Global Peptide Cancer Vaccine Market Size by Application
5.2.1 Global Peptide Cancer Vaccine Market Size Overview by Application (2019-2030)
5.2.2 Global Peptide Cancer Vaccine Historic Market Size Review by Application (2019-2024)
5.2.3 Global Peptide Cancer Vaccine Forecasted Market Size by Application (2025-2030)
5.3 Key Regions Market Size by Application
5.3.1 North America Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.2 Europe Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
5.3.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
6 Company Profiles
6.1 Boston Biomedical
6.1.1 Boston Biomedical Comapny Information
6.1.2 Boston Biomedical Business Overview
6.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
6.1.5 Boston Biomedical Recent Developments
6.2 Ultimovacs
6.2.1 Ultimovacs Comapny Information
6.2.2 Ultimovacs Business Overview
6.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
6.2.5 Ultimovacs Recent Developments
6.3 BrightPath Biotherapeutics
6.3.1 BrightPath Biotherapeutics Comapny Information
6.3.2 BrightPath Biotherapeutics Business Overview
6.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
6.3.5 BrightPath Biotherapeutics Recent Developments
6.4 TapImmune
6.4.1 TapImmune Comapny Information
6.4.2 TapImmune Business Overview
6.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
6.4.5 TapImmune Recent Developments
6.5 Immatics
6.5.1 Immatics Comapny Information
6.5.2 Immatics Business Overview
6.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
6.5.5 Immatics Recent Developments
6.6 Sellas
6.6.1 Sellas Comapny Information
6.6.2 Sellas Business Overview
6.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
6.6.5 Sellas Recent Developments
6.7 Imugene
6.7.1 Imugene Comapny Information
6.7.2 Imugene Business Overview
6.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
6.7.5 Imugene Recent Developments
6.8 VAXON Biotech
6.8.1 VAXON Biotech Comapny Information
6.8.2 VAXON Biotech Business Overview
6.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
6.8.5 VAXON Biotech Recent Developments
6.9 Generex Biotechnology
6.9.1 Generex Biotechnology Comapny Information
6.9.2 Generex Biotechnology Business Overview
6.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
6.9.5 Generex Biotechnology Recent Developments
6.10 ISA Pharmaceuticals
6.10.1 ISA Pharmaceuticals Comapny Information
6.10.2 ISA Pharmaceuticals Business Overview
6.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
6.10.5 ISA Pharmaceuticals Recent Developments
6.11 OncoTherapy Science
6.11.1 OncoTherapy Science Comapny Information
6.11.2 OncoTherapy Science Business Overview
6.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
6.11.5 OncoTherapy Science Recent Developments
7 North America by Country
7.1 North America Peptide Cancer Vaccine Sales by Country
7.1.1 North America Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.1.2 North America Peptide Cancer Vaccine Sales by Country (2019-2024)
7.1.3 North America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
7.2 North America Peptide Cancer Vaccine Market Size by Country
7.2.1 North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
7.2.2 North America Peptide Cancer Vaccine Market Size by Country (2019-2024)
7.2.3 North America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
8 Europe by Country
8.1 Europe Peptide Cancer Vaccine Sales by Country
8.1.1 Europe Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.1.2 Europe Peptide Cancer Vaccine Sales by Country (2019-2024)
8.1.3 Europe Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
8.2 Europe Peptide Cancer Vaccine Market Size by Country
8.2.1 Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
8.2.2 Europe Peptide Cancer Vaccine Market Size by Country (2019-2024)
8.2.3 Europe Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
9 Asia-Pacific by Country
9.1 Asia-Pacific Peptide Cancer Vaccine Sales by Country
9.1.1 Asia-Pacific Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.1.2 Asia-Pacific Peptide Cancer Vaccine Sales by Country (2019-2024)
9.1.3 Asia-Pacific Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
9.2 Asia-Pacific Peptide Cancer Vaccine Market Size by Country
9.2.1 Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
9.2.2 Asia-Pacific Peptide Cancer Vaccine Market Size by Country (2019-2024)
9.2.3 Asia-Pacific Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
10 Latin America by Country
10.1 Latin America Peptide Cancer Vaccine Sales by Country
10.1.1 Latin America Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.1.2 Latin America Peptide Cancer Vaccine Sales by Country (2019-2024)
10.1.3 Latin America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
10.2 Latin America Peptide Cancer Vaccine Market Size by Country
10.2.1 Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
10.2.2 Latin America Peptide Cancer Vaccine Market Size by Country (2019-2024)
10.2.3 Latin America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
11 Middle East and Africa by Country
11.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country
11.1.1 Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.1.2 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2019-2024)
11.1.3 Middle East and Africa Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
11.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Country
11.2.1 Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
11.2.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Country (2019-2024)
11.2.3 Middle East and Africa Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)
12 Value Chain and Sales Channels Analysis
12.1 Peptide Cancer Vaccine Value Chain Analysis
12.1.1 Peptide Cancer Vaccine Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Peptide Cancer Vaccine Production Mode & Process
12.2 Peptide Cancer Vaccine Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Peptide Cancer Vaccine Distributors
12.2.3 Peptide Cancer Vaccine Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings